NCT00171912View on ClinicalTrials.gov

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Hypereosinophilic SyndromeSystemic MastocytosisChronic Myelomonocytic LeukemiaDermatofibrosarcoma
Interventions
DRUG

imatinib mesylate

Trial Locations (1)

Unknown

Novartis Investigative Site, East Melbourne

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY